CDKN1A and autoimmune thrombocytopenic purpura: Taken together, our findings suggest that Eltrombopag may restore platelet counts in ITP patients in part by modulating CDKN1A expression in macrophages, thereby suppressing their hyperactive phagocytic behavior.